GSK plc
Healthy Returns: From Eli Lilly to Amazon, here are the latest health-care deals
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Good afternoon from San Francisco! This week, Ashley and I are attending the annual JPMorgan Health Care Conference – the largest gathering of biotech and pharma execs, […]
Read More
How we’re thinking about Eli Lilly after Trump picked obesity-drug critic RFK Jr. to run HHS
Enthusiasm for Club holding Eli Lilly needs to be tempered — at least for now — as Wall Street grapples with the possibility of a major shakeup to health policy in Washington. The news Republican President-elect Donald Trump on Thursday nominated prominent vaccine skeptic and obesity-drug critic Robert F. Kennedy Jr. to lead the Department […]
Read More
Stocks making the biggest moves midday: Palantir, Moderna, Ulta Beauty, Alibaba and more
Check out the companies making headlines in midday trading. Global pharma stocks — Shares of several vaccine makers declined after President-elect Donald Trump selected prominent vaccine skeptic Robert F. Kennedy Jr. as health secretary on Thursday. Shares of Moderna and Pfizer slipped nearly 9% and 5%, respectively. BioNTech , which helped develop a Covid vaccine with […]
Read More
Vaccine maker stocks fall as Trump chooses RFK Jr. to lead HHS
Independent presidential candidate Robert F. Kennedy Jr. makes an announcement on the future of his campaign in Phoenix, Arizona, U.S. August 23, 2024. Thomas Machowicz | Reuters Shares of vaccine makers fell on Thursday as President-elect Donald Trump nominated Robert F. Kennedy Jr., a prominent vaccine skeptic, to lead the Department of Health and Human […]
Read More
European markets fall over 1% as investors await UK budget; Campari shares slide 15%
Novo Nordisk shares fall to nine-month low Novo Nordisk shares on Wednesday fell to levels last seen in January of 2024 according to LSEG data, pulling back after competitor Eli Lilly posted weaker-than-expected quarterly results. Eli Lilly missed expectations for profit and revenue in the third quarter and cut its adjusted profit guidance for the […]
Read More
Merck says experimental RSV treatment protected infants in trial, paving way for potential approval
The logo for Merck is displayed on a screen at the New York Stock Exchange on Nov. 17, 2021. Andrew Kelly | Reuters Merck on Thursday said its experimental treatment designed to protect infants from respiratory syncytial virus showed positive results in a mid- to late-stage trial, bringing the company one step closer to filing […]
Read More
Healthy Returns: Weight loss drug Wegovy could face Medicare price negotiations next
Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. Hollie Adams | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Good afternoon! Wegovy, […]
Read More
Moderna to cut $1.1 billion in costs and launch 10 new products by 2027 as it charts post-Covid future
Moderna headquarters, exterior view, Cambridge, Massachusetts, USA. Plexi Images | GHI | UCG | Universal Images Group | Getty Images Moderna on Thursday said it plans to cut around $1.1 billion in expenses by 2027 and win approvals for several new products as it charts a path forward after the rapid decline of its Covid business. […]
Read More
Want to cash in on India’s growth? Veteran investor names 5 ‘well-run’ companies to buy right now
Interest in India has been rising steadily among investors, thanks to its growing economy , strong stock market performance and burgeoning population . Amid some talk of an Indian stock market bubble , however, Pramod Gubbi, co-founder of Marcellus Investment Managers, revealed how he is playing the market. The veteran investor said he is focused […]
Read More
Moderna stock falls more than 10% as it slashes guidance on low EU sales, tough U.S. vaccine market
Moderna on Thursday reported second-quarter revenue that beat expectations but slashed its full-year sales guidance, citing lower expected sales in Europe, a “competitive environment” for respiratory vaccines in the U.S. and the potential for deferred international revenue into 2025. The biotech company now expects 2024 product revenue to come in between $3 billion to $3.5 […]
Read More